| 000 | 01816 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513134748.0 | ||
| 264 | 0 | _c19980407 | |
| 008 | 199804s 0 0 eng d | ||
| 022 | _a0302-2838 | ||
| 024 | 7 |
_a10.1159/000019526 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTyrrell, C J | |
| 245 | 0 | 0 |
_aCasodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. _h[electronic resource] |
| 260 |
_bEuropean urology _c1998 |
||
| 300 |
_a39-53 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAcid Phosphatase _xblood |
| 650 | 0 | 4 |
_aAndrogen Antagonists _xpharmacokinetics |
| 650 | 0 | 4 |
_aAnilides _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEstradiol _xblood |
| 650 | 0 | 4 |
_aFollicle Stimulating Hormone _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLiver Function Tests |
| 650 | 0 | 4 |
_aLuteinizing Hormone _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeoplasm Invasiveness _xpathology |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xblood |
| 650 | 0 | 4 |
_aTestosterone _xblood |
| 650 | 0 | 4 | _aTosyl Compounds |
| 700 | 1 | _aDenis, L | |
| 700 | 1 | _aNewling, D | |
| 700 | 1 | _aSoloway, M | |
| 700 | 1 | _aChanner, K | |
| 700 | 1 | _aCockshott, I D | |
| 773 | 0 |
_tEuropean urology _gvol. 33 _gno. 1 _gp. 39-53 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000019526 _zAvailable from publisher's website |
| 999 |
_c9439990 _d9439990 |
||